TY - JOUR
T1 - Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling
AU - Nagai, Toshiyuki
AU - Anzai, Toshihisa
AU - Mano, Yoshinori
AU - Kaneko, Hidehiro
AU - Anzai, Atsushi
AU - Sugano, Yasuo
AU - Maekawa, Yuichiro
AU - Takahashi, Toshiyuki
AU - Yoshikawa, Tsutomu
AU - Fukuda, Keiichi
N1 - Funding Information:
We thank Hiromi Kato (Keio University) and Mayu Matsuda (Keio University) for excellent technical assistance, and Mochida Pharmaceutical Co., Ltd. for supplying EPA. This work was supported by a Medical School Faculty and Alumni Grant from Keio University Medical Science Fund (T.A.).
PY - 2013/5
Y1 - 2013/5
N2 - Serum C-reactive protein (CRP) elevation is associated with poor clinical outcome in patients with heart failure (HF). We previously reported that CRP exacerbates the development of pressure overload-induced cardiac remodeling through an enhanced inflammatory response and oxidative stress. In the present study, we examined the effect of eicosapentaenoic acid (EPA), a suppressor of inflammatory response and oxidative stress, on pressure overload-induced cardiac remodeling. Transverse aortic constriction (TAC) was performed on transgenic mice overexpressing CRP (CRPtg) and nontransgenic littermates (TAC/CON). CRPtg with TAC operation were randomly assigned to be fed a standard diet (TAC/CRPtg) or an EPA-enriched diet (7 % of total energy) (TAC/CRPtg/EPA). Myocardial mRNA level of transforming growth factor-β1, proinflammatory cytokines, and oxidative stress markers were increased in TAC/CRPtg in comparison with TAC/CON 1 and 4 weeks after the operation. These parameters were significantly suppressed in TAC/CRPtg/EPA compared with TAC/CRPtg. In addition, after 4 weeks of EPA treatment, as compared with TAC/CRPtg, TAC/CRPtg/EPA mice demonstrated reduced heart and lung weights, increased left ventricular fractional shortening, and decreased left ventricular end-diastolic pressure, together with decreased cardiac hypertrophy, fibrosis, and improved cardiac function. In conclusion, the anti-inflammatory and antioxidative properties of EPA may make it an effective therapeutic strategy for adverse cardiac remodeling associated with CRP overexpression.
AB - Serum C-reactive protein (CRP) elevation is associated with poor clinical outcome in patients with heart failure (HF). We previously reported that CRP exacerbates the development of pressure overload-induced cardiac remodeling through an enhanced inflammatory response and oxidative stress. In the present study, we examined the effect of eicosapentaenoic acid (EPA), a suppressor of inflammatory response and oxidative stress, on pressure overload-induced cardiac remodeling. Transverse aortic constriction (TAC) was performed on transgenic mice overexpressing CRP (CRPtg) and nontransgenic littermates (TAC/CON). CRPtg with TAC operation were randomly assigned to be fed a standard diet (TAC/CRPtg) or an EPA-enriched diet (7 % of total energy) (TAC/CRPtg/EPA). Myocardial mRNA level of transforming growth factor-β1, proinflammatory cytokines, and oxidative stress markers were increased in TAC/CRPtg in comparison with TAC/CON 1 and 4 weeks after the operation. These parameters were significantly suppressed in TAC/CRPtg/EPA compared with TAC/CRPtg. In addition, after 4 weeks of EPA treatment, as compared with TAC/CRPtg, TAC/CRPtg/EPA mice demonstrated reduced heart and lung weights, increased left ventricular fractional shortening, and decreased left ventricular end-diastolic pressure, together with decreased cardiac hypertrophy, fibrosis, and improved cardiac function. In conclusion, the anti-inflammatory and antioxidative properties of EPA may make it an effective therapeutic strategy for adverse cardiac remodeling associated with CRP overexpression.
KW - Cardiac remodeling
KW - Eicosapentaenoic acid
KW - Inflammatory response
KW - Oxidative stress
KW - Pressure overload
UR - http://www.scopus.com/inward/record.url?scp=84878698465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878698465&partnerID=8YFLogxK
U2 - 10.1007/s00380-012-0270-5
DO - 10.1007/s00380-012-0270-5
M3 - Article
C2 - 22875408
AN - SCOPUS:84878698465
SN - 0910-8327
VL - 28
SP - 404
EP - 411
JO - Heart and vessels
JF - Heart and vessels
IS - 3
ER -